SVBI — Interim / Quarterly Report 2021

Oct 1, 2021

Investor Conference 2021

==> picture [313 x 105] intentionally omitted <==

科妍生物科技股份有限公司 SciVision Biotech Inc.

Dr. Chun Chang Chen Project Manager | R&D Dept.

==> picture [66 x 17] intentionally omitted <==

This slide contains our business prospect, financial condition and sales which are derived from our prognosis existing internal/external data analysis. The actual result of operations may differ from the expressed or implied in these forward-looking statements due to various reasons, including but not limited to price fluctuation, competition, global economic condition, exchange rate fluctuation, market demand or other risks that beyond our control. The forward-looking statements in this release reflect the current belief of SciVision at this point and SciVision undertakes no obligation to update these statements with new information or future events.

==> picture [60 x 13] intentionally omitted <==

1. Company & Product &Technology Overview

2. Business Operation

==> picture [60 x 13] intentionally omitted <==

◼ Established in 2001

• Listed on TSE in 2013 (Code: 1786)

◼ Professional high-class, pharmaceutical-grade Hyaluronic Acid medical device production

◼ Two factories are located at No. 1, S. 1st Rd., and No. 9, S. 6th Rd., Qianzhen Dist., Kaohsiung City, Taiwan

• Follow to GMP, ISO 13485, US FDA and PIC/s GMP standards

◼ Produces at least 12 million syringes of medical device annually

==> picture [209 x 157] intentionally omitted <==

==> picture [256 x 78] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

(Crosslinked Hyaluronic Acid Platform, CHAP ® )

Cross-linking Knowledge Inspection method ® The application of CHAP CHAP technology can be made into products of various types and applications Absorbable Single-injection Dermal Other new application adhesion barrier viscosupplement filler category products

==> picture [60 x 13] intentionally omitted <==

International Partnership

==> picture [158 x 72] intentionally omitted <==

==> picture [171 x 61] intentionally omitted <==

==> picture [146 x 68] intentionally omitted <==

==> picture [164 x 68] intentionally omitted <==

==> picture [140 x 66] intentionally omitted <==

==> picture [161 x 112] intentionally omitted <==

==> picture [186 x 68] intentionally omitted <==

==> picture [140 x 58] intentionally omitted <==

==> picture [177 x 56] intentionally omitted <==

==> picture [175 x 54] intentionally omitted <==

==> picture [215 x 70] intentionally omitted <==

==> picture [109 x 65] intentionally omitted <==

==> picture [142 x 57] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Global market Applied field Items CAGR value in 2020 Facial Aesthetics Dermal Filler 1.8 billion 9.0 %

Synovial Fluid Geriatrics Care 2.3 billion 6.1 % Supplement Absorbable Surgery 3.3 billion 8.9 % Adhesion Barrier

Source:

1. Facial Aesthetics (Botulinum Toxin, Dermal Fillers), GlobalData

2. Hyaluronic Acid Viscosupplementation | Medtech 360 | Market Analysis | Global | 2019 , DRG 3. ANTI-ADHESION PRODUCTS 2012, Global Industry Analysts, Inc.

==> picture [60 x 13] intentionally omitted <==

Monophasic Fillers Biphasic Fillers (Smooth gel type) (Particle type)

==> picture [178 x 246] intentionally omitted <==

==> picture [125 x 179] intentionally omitted <==

==> picture [202 x 126] intentionally omitted <==

Product advantages ✓ High safety performance ✓ Strong structural support ✓ Shift resistance

Product advantages ✓ High safety performance ✓ Smooth and natural ✓ Easy operation

✓ Excellent viscoelasticity ✓ Sufficient active ingredients ✓ Good resistance to degradation

==> picture [60 x 13] intentionally omitted <==

==> picture [85 x 91] intentionally omitted <==

1. A Guide to Cheek Augmentation: Single-Point Deep Injection of Hyaluronic Acid Filler at Midface in Close Proximity to Medial Suborbicularis Oculi Fat (SOOF) Area. Journal of Cosmetics, Dermatological Sciences and Applications. 2016 Jan 06(01):1-8.

2. Use of High-Resolution Ultrasound (HRU) in the Assessment of Deep Injections of CHAP-Hyaluronic Acid (CHAP-HA) Fillers for Midface Lift. Journal of Cosmetics, Dermatological Sciences and Applications. 2018 Jan 08(03):126-132.

3. Dual-Plane Injection Technique With Microscale Tumescent Solution for Asian Rhinoplasty. Dermatol Surg. 2021 Jul 1;47(7):1015-1016.

4. CHAP–hyaluronic acid (CHAP-HA) filler as an optimal candidate for forehead filler augmentation using a 3-point injection technique. Journal of Cosmetics, Dermatological Sciences and Applications. 2021 Jan 11(02):76-83.

Product injected around the eye was safe and effective, with high usage satisfaction

==> picture [166 x 170] intentionally omitted <==

Product has good Develop injection Guidelines for tissue compatibility guidelines for high-risk forehead areas augmentation

==> picture [134 x 176] intentionally omitted <==

==> picture [167 x 170] intentionally omitted <==

==> picture [154 x 163] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Global market Applied field Items CAGR value in 2020 Facial Aesthetics Dermal Filler 1.8 billion 9.0 % Synovial Fluid Geriatrics Care 2.3 billion 6.1 % Supplement Absorbable Surgery 3.3 billion 8.9 % Adhesion Barrier

==> picture [60 x 13] intentionally omitted <==

Product category	Treatment description	Global CAGR of treatments	Products	Products
1-injection	Effect could be lasted for
regimen	more than half a year with	10.2%
(Long-acting)	administrating 1 syringe.		1 syringe per year	Anti-free Radical
			Super Long-Acting Type	Protection Type
	Effect could be lasted for
3-injection regimen	half a year with administrating 3 syringes continuously , 1 syringe	5.9%
	per week.		Best-selling products in Taiwan
	Effect could be lasted for
5-injection regimen	half a year with administrating 5 syringes continuously , 1 syringe	5.5%
	per week.

==> picture [60 x 13] intentionally omitted <==

Source: Hyaluronic Acid Viscosupplementation | Medtech 360 | Market Analysis | Global | 2019 , DRG

==> picture [85 x 91] intentionally omitted <==

1. The effect of three weekly intra-articular injections of hyaluronate on pain, function, and balance in patients with unilateral ankle arthritis. J Bone Joint Surg Am. 2011 Sep 21;93(18):1720-6.

2. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. Exp Gerontol. 2014 Apr;52:30-5.

3. Comparison of Single Intra-Articular Injection of Novel Hyaluronan (HYA-JOINT Plus) with Synvisc-One for Knee Osteoarthritis: A Randomized, Controlled, Double-Blind Trial of Efficacy and Safety. J Bone Joint Surg Am. 2017 Mar 15;99(6):462-471.

4. Origin and Efficacy of Hyaluronan Injections in Knee Osteoarthritis: Randomized, Double-Blind Trial. Med Sci Monit. 2018 Jul 9;24:4728-4737.

5. Improvement of self-reported functional scores and thickening of quadriceps and femoral intercondylar cartilage under ultrasonography after single intra-articular injection of a novel cross-linked hyaluronic acid in the treatment of knee osteoarthritis. J Back Musculoskelet Rehabil. 2018;31(4):709-718.

6. Safety and efficacy of single CHAP Hyaluronan injection versus three injections of linear Hyaluronan in pain relief for knee osteoarthritis: a prospective, 52-week follow-up, randomized, evaluator-blinded study. BMC Musculoskelet Disord. 2021 Jun 23;22(1):572.

7. Comparing efficacy of intraarticular single crosslinked Hyaluronan (HYAJOINT Plus) and platelet-rich plasma (PRP) versus PRP alone for treating knee osteoarthritis. Sci Rep. 2021 Jan 8;11(1):140.

The pain relief effect is better than Sanofi's one-injection produc.t

==> picture [195 x 114] intentionally omitted <==

The effect can be maintained for more The thickness of the quadriceps and than one year, with high satisfaction. cartilage improved significantly at 3 and 6 months after surgery.

==> picture [208 x 112] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

	Applied field Items Global market value in 2020 CAGR Facial Aesthetics Dermal Filler 1.8 billion 9.0 % Geriatrics Care Synovial Fluid Supplement 2.3 billion 6.1 % Surgery Absorbable Adhesion Barrier 3.3 billion 8.9 % Listed Core Products

For gynecological For ligament, peripheral pelvic surgery nerve, joint surgery

==> picture [240 x 142] intentionally omitted <==

==> picture [269 x 201] intentionally omitted <==

Product advantages ✓ High Biocompatibility ✓ Easy to apply ✓ Shift resistance

Product advantages ✓ High Biocompatibility ✓ Easy to apply ✓ Shift resistance ✓ Long effective protection time

==> picture [60 x 13] intentionally omitted <==

==> picture [85 x 91] intentionally omitted <==

1. A resorbable hyaluronic acid hydrogel to prevent adhesion in porcine model under laparotomy pelvic surgery. J Appl Biomater Funct Mater. Jan-Dec 2021;19.

2. Crosslinked Hyaluronic Acid Gels for the Prevention of Intrauterine Adhesions after a Hysteroscopic Myomectomy in Women with Submucosal Myomas: A Prospective, Randomized, Controlled Trial. Life. 2020 May 15;10(5):67.

3. Efficacy of Applying Hyaluronic Acid Gels in the Primary Prevention of Intrauterine Adhesion after Hysteroscopic Myomectomy: A Meta-Analysis of Randomized Controlled Trials. Life. 2020 Nov 15;10(11):285.

Product could effectively avoid or slow down the occurrence of postoperative adhesions.

Product could effectively avoid or slow down the occurrence of postoperative adhesions and was significantly better than competing products.

==> picture [314 x 265] intentionally omitted <==

==> picture [409 x 266] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

1. Company & Product &Technology Overview

2. Business Operation

==> picture [60 x 13] intentionally omitted <==

Profit & Loss-Consolidated Unit:NT thousand dollars (except for EPS) Revenue 238,033 100% 213,994 100% Cost of Goods Sold (72,918) -31% (61,433) -29% Gross Profit 165,115 69% 152,561 71% Operating Expense (100,765) -42% (88,098) -41% Operating Income 64,350 27% 64,463 30% Non-operating Income,Net (5,177) -2% 3,872 2% Income before Tax 59,173 25% 68,335 32% Net Income 56,269 24% 58,704 27% EPS(NT$) 0.92 0.96 H1,'21 (Reviewed) H1,'20 (Reviewed)	Profit & Loss-Consolidated Unit:NT thousand dollars (except for EPS) Revenue 238,033 100% 213,994 100% Cost of Goods Sold (72,918) -31% (61,433) -29% Gross Profit 165,115 69% 152,561 71% Operating Expense (100,765) -42% (88,098) -41% Operating Income 64,350 27% 64,463 30% Non-operating Income,Net (5,177) -2% 3,872 2% Income before Tax 59,173 25% 68,335 32% Net Income 56,269 24% 58,704 27% EPS(NT$) 0.92 0.96 H1,'21 (Reviewed) H1,'20 (Reviewed)	Profit & Loss-Consolidated Unit:NT thousand dollars (except for EPS) Revenue 238,033 100% 213,994 100% Cost of Goods Sold (72,918) -31% (61,433) -29% Gross Profit 165,115 69% 152,561 71% Operating Expense (100,765) -42% (88,098) -41% Operating Income 64,350 27% 64,463 30% Non-operating Income,Net (5,177) -2% 3,872 2% Income before Tax 59,173 25% 68,335 32% Net Income 56,269 24% 58,704 27% EPS(NT$) 0.92 0.96 H1,'21 (Reviewed) H1,'20 (Reviewed)	Profit & Loss-Consolidated Unit:NT thousand dollars (except for EPS) Revenue 238,033 100% 213,994 100% Cost of Goods Sold (72,918) -31% (61,433) -29% Gross Profit 165,115 69% 152,561 71% Operating Expense (100,765) -42% (88,098) -41% Operating Income 64,350 27% 64,463 30% Non-operating Income,Net (5,177) -2% 3,872 2% Income before Tax 59,173 25% 68,335 32% Net Income 56,269 24% 58,704 27% EPS(NT$) 0.92 0.96 H1,'21 (Reviewed) H1,'20 (Reviewed)	11.2% 18.7% 8.2% 14.4% -0.2% -233.7% -13.4% -4.1% Annual growth rate
	H1,'21 (Reviewed)		H1,'20 (Reviewed)
	238,033 100% (72,918) -31% 165,115 69% (100,765) -42% 64,350 27% (5,177) -2% 59,173 25% 56,269 24%		213,994 100% (61,433) -29% 152,561 71% (88,098) -41% 64,463 30% 3,872 2% 68,335 32% 58,704 27%
	0.92		0.96

2021 Jan.~Jun. & 2020 Jan.~Jun.

==> picture [613 x 374] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

2021 Jan.~Jun. & 2020 Jan.~Jun.

==> picture [675 x 376] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

	Balance Sheet-Consolidated Unit:NT thousand dollars Cash and Cash Equivalents 616,055 27% 293,159 15% Accounts Receivable 67,496 3% 55,371 3% Inventories 52,797 2% 31,106 2% Current Financial Assets at Fair Value through Profit or Loss - 0% 53,500 3% Amortized Cost Financial Assets 99,927 4% 133,998 7% Property,Plant & Equipment 1,283,340 56% 1,257,559 65% Other Current/Non-Current Assets 160,944 7% 98,546 5% Total Assets 2,280,559 100% 1,923,239 100% Current Liabilities 421,933 18% 226,328 11% Long-Term & Other Liabilities 398,194 17% 356,766 19% Total Liabilities 820,127 36% 583,094 30% Total Shareholders' Equities 1,460,432 64% 1,340,145 70% Key Indices A/R Turnover (Days) 51.90 49.69 Inventory Turnover (Days) 123.51 95.14 Current Ratio(x) 205.56% 262.75% Net Profit Margin(%) 23.64% 27.43% 2021/6/30 (Reviewed) 2020/6/30 (Reviewed)	Balance Sheet-Consolidated Unit:NT thousand dollars Cash and Cash Equivalents 616,055 27% 293,159 15% Accounts Receivable 67,496 3% 55,371 3% Inventories 52,797 2% 31,106 2% Current Financial Assets at Fair Value through Profit or Loss - 0% 53,500 3% Amortized Cost Financial Assets 99,927 4% 133,998 7% Property,Plant & Equipment 1,283,340 56% 1,257,559 65% Other Current/Non-Current Assets 160,944 7% 98,546 5% Total Assets 2,280,559 100% 1,923,239 100% Current Liabilities 421,933 18% 226,328 11% Long-Term & Other Liabilities 398,194 17% 356,766 19% Total Liabilities 820,127 36% 583,094 30% Total Shareholders' Equities 1,460,432 64% 1,340,145 70% Key Indices A/R Turnover (Days) 51.90 49.69 Inventory Turnover (Days) 123.51 95.14 Current Ratio(x) 205.56% 262.75% Net Profit Margin(%) 23.64% 27.43% 2021/6/30 (Reviewed) 2020/6/30 (Reviewed)	Balance Sheet-Consolidated Unit:NT thousand dollars Cash and Cash Equivalents 616,055 27% 293,159 15% Accounts Receivable 67,496 3% 55,371 3% Inventories 52,797 2% 31,106 2% Current Financial Assets at Fair Value through Profit or Loss - 0% 53,500 3% Amortized Cost Financial Assets 99,927 4% 133,998 7% Property,Plant & Equipment 1,283,340 56% 1,257,559 65% Other Current/Non-Current Assets 160,944 7% 98,546 5% Total Assets 2,280,559 100% 1,923,239 100% Current Liabilities 421,933 18% 226,328 11% Long-Term & Other Liabilities 398,194 17% 356,766 19% Total Liabilities 820,127 36% 583,094 30% Total Shareholders' Equities 1,460,432 64% 1,340,145 70% Key Indices A/R Turnover (Days) 51.90 49.69 Inventory Turnover (Days) 123.51 95.14 Current Ratio(x) 205.56% 262.75% Net Profit Margin(%) 23.64% 27.43% 2021/6/30 (Reviewed) 2020/6/30 (Reviewed)
	Unit:NT thousand dollars	2021/6/30 (Reviewed)	2020/6/30 (Reviewed)
	Cash and Cash Equivalents Accounts Receivable Inventories Current Financial Assets at Fair Value through Profit or Loss Amortized Cost Financial Assets Property,Plant & Equipment Other Current/Non-Current Assets Total Assets Current Liabilities	616,055 27% 67,496 3% 52,797 2% - 0% 99,927 4% 1,283,340 56% 160,944 7%	293,159 15% 55,371 3% 31,106 2% 53,500 3% 133,998 7% 1,257,559 65% 98,546 5% 1,923,239 100% 226,328 11%
		2,280,559 100%
		421,933 18%
	Long-Term & Other Liabilities Total Liabilities Total Shareholders' Equities Key Indices A/R Turnover (Days) Inventory Turnover (Days) Current Ratio(x) Net Profit Margin(%)	398,194 17%	356,766 19%
		820,127 36%	583,094 30%
		1,460,432 64%	1,340,145 70%
		51.90 123.51 205.56% 23.64%	49.69 95.14 262.75% 27.43%

	Cash Flows-Consolidated Unit:NT thousand dollars From Operating Activities Profit before tax Depreciation & Amortisation Net change in working capital From Investing Activities amortised cost through Profit or Loss Capital expenditure Net change in Investing item From Financing Activities Short-term loans Long-term loans Net change in Fincncing item Net Change in Cash Beginning Balance Ending Balance Free Cash Flow (8,704) (7,519) (150,905) (104,971) 0 67,689 59,173 68,335 19,730 6,873 54,935 49,909 616,055 293,159 (84,175) (38,391) (15,264) (17,780) 0 (603) (606) 218,691 (37,888) 397,364 331,047 299,397 (606) 0 0 300,000 (51,466) (50,000) 1,200 H1,'21 (Reviewed) H1,'20 (Reviewed) 70,199	Cash Flows-Consolidated Unit:NT thousand dollars From Operating Activities Profit before tax Depreciation & Amortisation Net change in working capital From Investing Activities amortised cost through Profit or Loss Capital expenditure Net change in Investing item From Financing Activities Short-term loans Long-term loans Net change in Fincncing item Net Change in Cash Beginning Balance Ending Balance Free Cash Flow (8,704) (7,519) (150,905) (104,971) 0 67,689 59,173 68,335 19,730 6,873 54,935 49,909 616,055 293,159 (84,175) (38,391) (15,264) (17,780) 0 (603) (606) 218,691 (37,888) 397,364 331,047 299,397 (606) 0 0 300,000 (51,466) (50,000) 1,200 H1,'21 (Reviewed) H1,'20 (Reviewed) 70,199	Cash Flows-Consolidated Unit:NT thousand dollars From Operating Activities Profit before tax Depreciation & Amortisation Net change in working capital From Investing Activities amortised cost through Profit or Loss Capital expenditure Net change in Investing item From Financing Activities Short-term loans Long-term loans Net change in Fincncing item Net Change in Cash Beginning Balance Ending Balance Free Cash Flow (8,704) (7,519) (150,905) (104,971) 0 67,689 59,173 68,335 19,730 6,873 54,935 49,909 616,055 293,159 (84,175) (38,391) (15,264) (17,780) 0 (603) (606) 218,691 (37,888) 397,364 331,047 299,397 (606) 0 0 300,000 (51,466) (50,000) 1,200 H1,'21 (Reviewed) H1,'20 (Reviewed) 70,199
	Unit:NT thousand dollars	H1,'21 (Reviewed)	H1,'20 (Reviewed)
	From Operating Activities	70,199	67,689
	Profit before tax Depreciation & Amortisation Net change in working capital	(8,704) 59,173 19,730	(7,519) 68,335 6,873
	From Investing Activities	(150,905)	(104,971)
	amortised cost through Profit or Loss Capital expenditure Net change in Investing item	(84,175) (15,264) 0 (51,466)	(38,391) (17,780) (50,000) 1,200
	From Financing Activities	299,397	(606)
	Short-term loans Long-term loans Net change in Fincncing item	(603) 0 300,000	0 (606) 0
	Net Change in Cash	218,691	(37,888)
	Beginning Balance	397,364	331,047
	Ending Balance	616,055	293,159
	Free Cash Flow	54,935	49,909

Million dollars

Million dollars

Revenue

Net Profit

Gross and Operating Margin

==> picture [342 x 155] intentionally omitted <==

Cash Generated From Operations Before Interest And Taxes

Million dollars

==> picture [60 x 13] intentionally omitted <==

Science Creates Better Visions

==> picture [60 x 13] intentionally omitted <==